• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Coya Therapeutics Inc.

    5/16/25 5:05:18 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COYA alert in real time by email
    DEFA14A 1 d874014ddefa14a.htm DEFA14A DEFA14A
     
     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    COYA THERAPEUTICS, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

     

     2025 Stockholder Meeting Notice    LOGO

    Important Notice Regarding the Availability of Proxy Materials for the

    Coya Therapeutics, Inc. Stockholder Meeting to be Held on June 26, 2025.

    Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 Proxy Statement; Annual Report on Form 10-K for the Year Ended December 31, 2024 are available at:

     

    www.envisionreports.com/COYA

     

     

    LOGO

     

    Easy Online Access – View your proxy materials and vote.

     

      Step 1:    Go to www.envisionreports.com/COYA.
      Step 2:    Click on Cast Your Vote or Request Materials.
      Step 3:    Follow the instructions on the screen to log in.
      Step 4:    Make your selections as instructed on each screen for your delivery preferences.
      Step 5:    Vote your shares.

    When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.

     

     

     

    LOGO   Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 26, 2025 to facilitate timely delivery.

     

    ⬛   2NOT   COY   LOGO

    045JMB


     
     2025 Stockholder Meeting Notice

    Coya Therapeutics, Inc. Annual Meeting of Stockholders will be held on June 26, 2025, virtually at meetnow.global/MJYXQX7, at 12:00 p.m. Central Time.

    Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations.

    The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposal 2:

     

      1.

    Election of Directors:

    01 - Howard Berman, Ph.D.

    02 - Arun Swaminathan, Ph.D.

    03 - Ann Lee, Ph.D.

      2.

    Ratify the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent public accounting firm for the year ending December 31, 2025

    PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.

     

     

     

     

    LOGO   

    Here’s how to order a copy of the proxy materials and select delivery preferences:

     

    Current and future delivery requests can be submitted using the options below.

     

    If you request an email copy, you will receive an email with a link to the current meeting materials.

     

    PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

     

    –   Internet – Go to www.envisionreports.com/COYA. Click Cast Your Vote or Request Materials.

     

    –   Phone – Call us free of charge at 1-866-641-4276.

     

    –   Email – Send an email to [email protected] with “Proxy Materials Coya Therapeutics, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

     

    To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 26, 2025.

    Get the next $COYA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COYA

    DatePrice TargetRatingAnalyst
    12/4/2024$15.00Buy
    D. Boral Capital
    More analyst ratings

    $COYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Snyder David S bought $12,934 worth of shares (1,800 units at $7.19), increasing direct ownership by 26% to 8,800 units (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/14/24 6:08:32 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Swaminathan Arun bought $36,797 worth of shares (5,000 units at $7.36), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/13/24 4:05:16 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Grossman Fred bought $19,973 worth of shares (2,710 units at $7.37) (SEC Form 4)

      4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

      11/12/24 6:03:34 PM ET
      $COYA
      Biotechnology: Pharmaceutical Preparations
      Health Care